EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

Fruquintinib Plus TAS ‐102 With or Without SBRT as Third‐ Or Later‐Line Therapy for Metastatic Colorectal Cancer: Preliminary Results From a Prospective Phase II Trial

Yi Wang iD, Jianfen Xu, Linchun Liang, Yunjie Chen, Leizheng Fei, Jing Hu, Jianjiong Li, Yi Lu, Feng Ren, Ke Chen, Yanping Shen, Qingsong Tao iD und 8 weitere

Cancer Medicine · 2026-05 · 15 (5)

DOI: 10.1002/cam4.71884 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer Medicine, online erschienen am 29.04.2026. Verfasst von Yi Wang und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiotherapy and Chemotherapy, Ningbo No. 2 Hospital, Ningbo, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Trifluridine, Uracil, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Medical and Health Science Program of Zhejiang Province, Shanghai YRD Foundation for Innovation in Health Industry.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Both fruquintinib and TAS‐102 monotherapies are guideline‐recommended for third‐line treatment of metastatic colorectal cancer (mCRC). This study aimed to analyze the preliminary outcomes of fruquintinib combined with TAS‐102, with or without stereotactic body radiation therapy (SBRT), as a third‐ or later‐line therapy for mCRC. This prospective, two‐arm, phase II study planned to enroll 66 patients with mCRC who were unresponsive to at least two prior lines of therapy. Patients were allocated to either the FTS (fruquintinib + TAS‐102 + SBRT) or FT (fruquintinib + TAS‐102) group. Eligible patients received fruquintinib (4 mg, qd, days 1–21) and TAS‐102 (30 mg/m 2 , bid, days 1–5; 15–19) orally every 4 weeks until disease progression or intolerable toxicity. The primary endpoint was progression‐free survival (PFS, per RECIST 1.1); secondary endpoints included overall survival (OS), objective response rate (ORR), disease control rate (DCR), and adverse events (AEs, graded using CTCAE v5.0). By January 20, 2025, 40 patients were enrolled (FTS group, 11; FT group, 29), with a median follow‐up of 8.48 months. In 20 (50%) patients, the number of metastatic organs was ≥ 3. However, the number of metastatic lesions was > 5 in 32 (80%) patients. For the 36 eligible patients, the ORR and DCR were 19.4% and 88.9%, respectively. The median PFS was 8.58 months; however, the median OS has not been attained. The most common treatment‐related AE was decreased white blood cell count (92.5%); grade 3–4 AEs included decreased lymphocyte count (12.5%). No treatment‐related death occurred. Fruquintinib combined with TAS‐102, with or without SBRT, showed promising preliminary efficacy and acceptable safety as third‐ or later‐line treatment of mCRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsTrifluridineUracilAntineoplastic Combined Chemotherapy ProtocolsQuinazolinesBenzofuransRadiosurgeryHumansFemaleMaleProspective StudiesThyminePyrrolidinesDrug CombinationsAgedMiddle AgedAdultAged, 80 and overNeoplasm MetastasisProgression-Free SurvivalTreatment Outcome

Stichwörter der Autor:innen

SBRTTAS‐102fruquintinibmetastatic colorectal cancer

Substanzen

Trifluridinetrifluridine tipiracil drug combinationUracilThyminePyrrolidinesDrug CombinationsQuinazolinesBenzofuransHMPL-013

Autor:innen und Institutionen

  • Department of Radiotherapy and Chemotherapy, Ningbo No. 2 Hospital, Ningbo, China.
  • Department of Medical Oncology, Ningbo No. 2 Hospital, Ningbo, China.
  • Oncology Department, Ningbo Mingzhou Hospital, Ningbo, China.
  • Hepatopancreatobiliary Surgery Department 2, Ningbo No. 2 Hospital, Ningbo, China.
  • Department of Anorectal Surgery, Ningbo Medical Center, Lihuili Hospital, Ningbo, China.
  • Department of Oncology Radiotherapy and Chemotherapy, The Affiliated Lihuili Hospital of Ningbo University, Ningbo, China.

ORCID-Profile: Yi Wang, Qingsong Tao, Yunbao Xu, Chen Zhang

Förderung

  • Medical and Health Science Program of Zhejiang Province
  • Shanghai YRD Foundation for Innovation in Health Industry

Zitieren

APA

Wang, Y., Xu, J., Liang, L., Chen, Y., Fei, L., Hu, J., Li, J., Lu, Y., Ren, F., Chen, K., Shen, Y., Tao, Q., Fang, Z., Liu, K., Ye, H., Zhang, J., Xu, Y., Mao, H., Zhang, C., & Rao, C. (2026). Fruquintinib Plus TAS ‐102 With or Without SBRT as Third‐ Or Later‐Line Therapy for Metastatic Colorectal Cancer: Preliminary Results From a Prospective Phase II Trial. Cancer Medicine, 15(5). https://doi.org/10.1002/cam4.71884

Vancouver

Wang Y, Xu J, Liang L, Chen Y, Fei L, Hu J, et al. Fruquintinib Plus TAS ‐102 With or Without SBRT as Third‐ Or Later‐Line Therapy for Metastatic Colorectal Cancer: Preliminary Results From a Prospective Phase II Trial. Cancer Medicine. 2026;15(5). doi:10.1002/cam4.71884

BibTeX
@article{Wang2026,
  author = {Wang, Yi and Xu, Jianfen and Liang, Linchun and Chen, Yunjie and Fei, Leizheng and Hu, Jing and Li, Jianjiong and Lu, Yi and Ren, Feng and Chen, Ke and Shen, Yanping and Tao, Qingsong and Fang, Zhi and Liu, Kaitai and Ye, Hua and Zhang, Jing and Xu, Yunbao and Mao, Haoxun and Zhang, Chen and Rao, Chuangzhou},
  title = {Fruquintinib Plus TAS ‐102 With or Without SBRT as Third‐ Or Later‐Line Therapy for Metastatic Colorectal Cancer: Preliminary Results From a Prospective Phase II Trial},
  journal = {Cancer Medicine},
  year = {2026},
  volume = {15},
  number = {5},
  doi = {10.1002/cam4.71884}
}
Kostenlos starten →